Osteochondral Allograft (Fresh Talar Allograft)

Survival Rates (Systematic Review of 522 ankles)

→ Uses cartilage+bone from a deceased donor (cadaver) instead of your own body. Like an organ transplant for cartilage. Advantage: no donor site pain. Downside: potential rejection, tissue isn't "alive" like yours.

2024 Systematic Review Update

A 2024 comprehensive review of fresh osteochondral allograft (OCA) outcomes [79]:

• Fresh OCA has become the preferred treatment for large OLT (>150 mm²)
  → OCA = Osteochondral Allograft (bone + cartilage from a donor)
• Graft viability critical: optimal implantation within 28 days of harvest
  → Viability = cells are still alive; fresh grafts need to be implanted quickly before cells die
• 5-year survival rates: 85-92% when proper tissue banking protocols followed

Donor Age and Storage Time, From Bugbee's Own Registry (Added August 11, 2026)

Two new papers from the Scripps allograft program — Dr. Bugbee is senior author on both — put numbers on graft-selection variables this page had only carried as a single “28-day window” rule. Both are knee series, not talus, but they come from the exact program and surgeon this site's allograft thread points at, so the questions transfer even if the numbers don't.

• Donor age mattered a lot. In 236 primary fresh OCAs (mean 8.2-year follow-up), grafts from donors older than 20 failed at 11.7% vs 3.7% for donors 20 and under — 10-year survivorship 89.3% vs 100%, a ~7× hazard [409]
  → The younger the donor's cartilage, the more of its cells survive — and in this series no graft from a donor 20 or under had failed at 10 years
• Storage time inside the 28-day window did not behave as expected. Grafts released early (1–14 days) failed at 22.7% vs 6.0% for late-release grafts (15–28 days) [409]. Association, not causation — but it means the standing “implant as fresh as possible” intuition has no support in the program's own registry, and scheduling logistics inside the window are not a reason to worry
• Donor BMI and donor-recipient sex matching made no difference to failure or outcomes [409]
• Failures are front-loaded. In the companion 288-knee series with minimum 10-year follow-up (median patient age 33), overall survivorship was 78% at 10 years, but annual failure ran 4.9%/year in the first 3 years and then dropped to 1.5%/year through year 10 [410]
  → If a graft makes it through its first three years, its yearly risk falls by about two-thirds. The 2012 graft here did exactly that — cleared the risky early window, then declined late

What this changes for the consult: donor age is a graft-selection variable the patient can actually ask about — whether the program requests young-donor tissue for a young recipient, and whether the graft bank reports donor age at release. It was not previously on this site's question list.

2025 Fresh Allograft Outcomes Study

Recent 2025 data on fresh talar allografts [80]:

Long-Term Data (Gross et al.)

• 12-year mean follow-up: 6/9 grafts remained viable [43]
• 3 patients required fusion due to graft resorption/fragmentation [43]
• Success rates range from 73-100% across studies [43]

Bulk vs Shell Allograft Comparison (2024)

A 2024 comparative analysis evaluated bulk hemitalar vs shell allografts [81]:

• Shell grafts: Better incorporation rates, lower revision rates
• Bulk hemitalar: Reserved for massive defects (>50% talar dome)
• Surgeon experience significantly impacts outcomes

Revision Options After Failed Allograft

Systematic review of 115 failed bulk allografts [44]:

• Ankle arthrodesis: 34 cases (most common)
• Revision allograft: 30 cases
• Total ankle arthroplasty: 20 cases
• Mean time to revision: 53.3 months

2024 Fresh OCA Long-Term Follow-Up (9.2 Years)

A 2024 study with mean 9.2-year follow-up provided the strongest recent supportive data [153]:

• 50% were still participating in sports at latest follow-up
• Concluded fresh OCA is reasonable for young active patients who failed prior surgery or have massive defects

2024-2025 Revision Allograft Outcomes

New data on revision allograft surgery [82]:

• Revision OCA has lower success rates than primary (68% vs 87%)
• Prior surgery type affects revision outcomes
• Failed BMS prior to OCA does not negatively impact OCA success

2024 Pooled Revision Evidence

The 2024 non-primary OLT systematic review (50 studies, 806 ankles) found less favorable pooled results for OCA as a revision procedure [148]:

• OCA did not significantly improve pooled AOFAS or pain outcomes in revision cases
• Clinical failures occurred in 14 of 72 OCA cases (19%)
• OCA and HemiCAP looked less effective as revision procedures than ACI or OAT

Critical for Raymond: A heterogeneous level-IV review found higher odds of revision (OR 7.2) and failure (OR 5.1) for allograft than autograft at midterm [38]. It did not compare a second allograft with a first allograft and does not estimate this patient's probability of repeat-allograft failure. The first graft lasting 12 years remains a meaningful personal data point.